Hans Bishop, Grail CEO (Victor J. Blue/Bloomberg via Getty Images)
September 9, 2020 10:31 AM EDTUpdated 11:52 AM
People
Financing

$1.6 bil­lion liq­uid biop­sy play­er Grail files IPO, re­veal­ing 2021 com­mer­cial plans and a Mi­das-sized $65M pay pack­age for Hans Bish­op

Jason Mast

Editor

The hunt for the Grail just got a lot eas­i­er. In fact, in a few weeks you’ll like­ly be able to pick up a por­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times